| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD010227 |
| P3181 | OpenCitations bibliographic resource ID | 2168385 |
| P50 | author | Claire Bombardier | Q28322236 |
| Deborah Marshall | Q38544106 | ||
| George Tomlinson | Q41526116 | ||
| Glen Hazlewood | Q56797844 | ||
| P2093 | author name string | Cheryl Barnabe | |
| P2860 | cites work | Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis | Q24235784 |
| Combination therapy in rheumatoid arthritis | Q74209980 | ||
| Expressing findings from meta-analyses of continuous outcomes in terms of risks | Q84725756 | ||
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Evolving concepts of rheumatoid arthritis | Q29618020 | ||
| Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes | Q30494910 | ||
| Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis | Q33567430 | ||
| Generalized linear mixed models for meta-analysis | Q33594559 | ||
| A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial | Q33675468 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs | Q34110066 | ||
| 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q34130671 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
| American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Q34782898 | ||
| Epidemiology and burden of illness of rheumatoid arthritis | Q35780338 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Genes, environment and immunity in the development of rheumatoid arthritis | Q36607737 | ||
| Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons | Q37167644 | ||
| An update on methotrexate | Q37448004 | ||
| Checking consistency in mixed treatment comparison meta-analysis | Q37705195 | ||
| Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. | Q37744201 | ||
| Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis | Q37744356 | ||
| Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. | Q37888895 | ||
| Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs | Q37932896 | ||
| Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. | Q37998319 | ||
| Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films | Q41513883 | ||
| Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial | Q41937791 | ||
| Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. | Q46894544 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative | Q48416663 | ||
| Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities | Q70642560 | ||
| P921 | main subject | rheumatoid arthritis | Q187255 |
| methotrexate | Q422232 | ||
| P577 | publication date | 2013-01-31 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis |
Search more.